These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 26340464)
1. Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis? Samoš M; Fedor M; Kovář F; Duraj L; Stančiaková L; Galajda P; Staško J; Kubisz P; Mokáň M Blood Coagul Fibrinolysis; 2016 Mar; 27(2):117-20. PubMed ID: 26340464 [TBL] [Abstract][Full Text] [Related]
2. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884 [TBL] [Abstract][Full Text] [Related]
3. In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention. Brice AE; Hernandez GA; Sanchez M; Haynick M; Mendoza CE Platelets; 2017 May; 28(3):305-309. PubMed ID: 27778525 [TBL] [Abstract][Full Text] [Related]
4. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Steg PG; Harrington RA; Emanuelsson H; Katus HA; Mahaffey KW; Meier B; Storey RF; Wojdyla DM; Lewis BS; Maurer G; Wallentin L; James SK; Circulation; 2013 Sep; 128(10):1055-65. PubMed ID: 23900047 [TBL] [Abstract][Full Text] [Related]
5. Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. Azmoon S; Angiolillo DJ Catheter Cardiovasc Interv; 2013 Feb; 81(2):232-42. PubMed ID: 22581463 [TBL] [Abstract][Full Text] [Related]
6. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525 [TBL] [Abstract][Full Text] [Related]
7. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry. Mayer K; Schulz S; Bernlochner I; Morath T; Braun S; Hausleiter J; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D Thromb Haemost; 2014 Aug; 112(2):342-51. PubMed ID: 24718389 [TBL] [Abstract][Full Text] [Related]
8. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry. El Ghannudi S; Ohlmann P; Meyer N; Wiesel ML; Radulescu B; Chauvin M; Bareiss P; Gachet C; Morel O JACC Cardiovasc Interv; 2010 Jun; 3(6):648-56. PubMed ID: 20630458 [TBL] [Abstract][Full Text] [Related]
9. Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: Results From the European PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort Registry. Godschalk TC; Byrne RA; Adriaenssens T; Malik N; Feldman LJ; Guagliumi G; Alfonso F; Neumann FJ; Trenk D; Joner M; Schulz C; Steg PG; Goodall AH; Wojdyla R; Dudek D; Wykrzykowska JJ; Hlinomaz O; Zaman AG; Curzen N; Dens J; Sinnaeve P; Desmet W; Gershlick AH; Kastrati A; Massberg S; Ten Berg JM; JACC Cardiovasc Interv; 2017 Dec; 10(24):2548-2556. PubMed ID: 29268884 [TBL] [Abstract][Full Text] [Related]
10. Ticagrelor as an alternative in clopidogrel-associated neutropenia. Shah R; Keough LA; Belalcazar-Portacio A; Ramanathan KB Platelets; 2015; 26(1):80-2. PubMed ID: 24433137 [TBL] [Abstract][Full Text] [Related]
11. "Conversations in cardiology": How do you pick the best antiplatelet drug--clopidogrel, prasugrel, ticagrelor for your PCI patient? Kern MJ Catheter Cardiovasc Interv; 2012 Feb; 79(2):255-62. PubMed ID: 22271555 [No Abstract] [Full Text] [Related]
12. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. Cuisset T; Frere C; Quilici J; Gaborit B; Castelli C; Poyet R; Bali L; Morange PE; Alessi MC; Bonnet JL Am J Cardiol; 2009 Oct; 104(8):1078-82. PubMed ID: 19801028 [TBL] [Abstract][Full Text] [Related]
13. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. Tantry US; Bonello L; Aradi D; Price MJ; Jeong YH; Angiolillo DJ; Stone GW; Curzen N; Geisler T; Ten Berg J; Kirtane A; Siller-Matula J; Mahla E; Becker RC; Bhatt DL; Waksman R; Rao SV; Alexopoulos D; Marcucci R; Reny JL; Trenk D; Sibbing D; Gurbel PA; J Am Coll Cardiol; 2013 Dec; 62(24):2261-73. PubMed ID: 24076493 [TBL] [Abstract][Full Text] [Related]
14. How Long Does It Take for Clopidogrel and Ticagrelor to Inhibit Platelets in Patients Undergoing Primary Percutaneous Coronary Intervention? A Detailed Pharmacodynamic Analysis: Time Course of Platelet Reactivity in STEMI (TOPS). Bergmeijer TO; Godschalk TC; Janssen PWA; Berge KVD; Breet NJ; Kelder JC; Hackeng CM; Ten Berg JM Semin Thromb Hemost; 2017 Jun; 43(4):439-446. PubMed ID: 28561235 [TBL] [Abstract][Full Text] [Related]
16. Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor. Nardin M; Verdoia M; Sartori C; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G; J Cardiovasc Pharmacol; 2015 Oct; 66(4):364-70. PubMed ID: 26065844 [TBL] [Abstract][Full Text] [Related]
17. New anti-platelet agents: the end of resistance? Kastrati A Thromb Res; 2012 Oct; 130 Suppl 1():S53-5. PubMed ID: 23026663 [TBL] [Abstract][Full Text] [Related]
18. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry. Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891 [TBL] [Abstract][Full Text] [Related]
19. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250 [TBL] [Abstract][Full Text] [Related]
20. Stent thrombosis after primary percutaneous coronary intervention in comatose survivors of out-of-hospital cardiac arrest: Are the new P2Y12 inhibitors really more effective than clopidogrel? Gouffran G; Rosencher J; Bougouin W; Jakamy R; Joffre J; Lamhaut L; Dumas F; Cariou A; Varenne O Resuscitation; 2016 Jan; 98():73-8. PubMed ID: 26610376 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]